Holen Sie sich die Stockscreener-App
85.11
0.82%
-0.70
Handel nachbörslich:
85.57
0.46
+0.54%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$85.81
Offen:
$85.49
24-Stunden-Volumen:
5.50M
Relative Volume:
0.78
Marktkapitalisierung:
$105.58B
Einnahmen:
$33.20B
Nettoeinkommen (Verlust:
$4.26B
KGV:
25.87
EPS:
3.29
Netto-Cashflow:
$5.47B
1W Leistung:
+3.39%
1M Leistung:
+2.67%
6M Leistung:
-3.25%
1J Leistung:
+1.90%
1-Tages-Spanne:
$84.81
$85.80
1-Wochen-Bereich:
$81.87
$86.25
52-Wochen-Spanne:
$75.96
$96.25
Medtronic Plc Stock (MDT) Company Profile
Firmenname
Medtronic Plc
Sektor
Branche
Telefon
01135314381700
Adresse
BUILDING TWO PARKMORE BUSINESS PARK WEST, GALWAY
Vergleichen Sie MDT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MDT
Medtronic Plc
|
85.11 | 105.58B | 33.20B | 4.26B | 5.47B | 3.29 |
|
ABT
Abbott Laboratories
|
129.05 | 231.50B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.95 | 154.04B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
387.53 | 144.27B | 23.22B | 2.86B | 3.58B | 7.40 |
|
EW
Edwards Lifesciences Corp
|
75.50 | 43.95B | 5.54B | 4.18B | 623.10M | 7.00 |
Medtronic Plc Stock (MDT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-04 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-10-10 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-08-21 | Bestätigt | Oppenheimer | Perform |
| 2024-08-15 | Hochstufung | UBS | Sell → Neutral |
| 2024-08-14 | Herabstufung | Stifel | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Sell |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-06-30 | Eingeleitet | CL King | Buy |
| 2023-05-30 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-04-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-29 | Herabstufung | UBS | Buy → Sell |
| 2023-01-09 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-11-23 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-11-23 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-11-16 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-13 | Eingeleitet | Mizuho | Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-08-24 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-07-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-06-01 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-05-27 | Herabstufung | Needham | Buy → Hold |
| 2022-04-13 | Herabstufung | Truist | Buy → Hold |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-01-10 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-01-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-01-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-17 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-12-16 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-06-10 | Fortgesetzt | Cowen | Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Equal Weight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-12-15 | Hochstufung | Goldman | Sell → Neutral |
| 2020-12-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-10-08 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2020-10-08 | Hochstufung | Stifel | Hold → Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-05-14 | Herabstufung | DZ Bank | Buy → Hold |
| 2020-03-30 | Herabstufung | Needham | Strong Buy → Buy |
| 2020-03-25 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Sell |
| 2020-01-08 | Eingeleitet | SunTrust | Buy |
| 2020-01-02 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-06-05 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2019-02-04 | Bestätigt | Needham | Strong Buy |
| 2019-01-03 | Eingeleitet | Deutsche Bank | Buy |
| 2019-01-02 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-12-19 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-11-28 | Eingeleitet | UBS | Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-08-27 | Bestätigt | Argus | Buy |
Alle ansehen
Medtronic Plc Aktie (MDT) Neueste Nachrichten
Product liability lawsuits target Medtronic, Boston Scientific spinal cord stim tech - MassDevice
Electroceuticals Market Top PlayersMedtronic Plc (Ireland), - openPR.com
Weak Financial Prospects Seem To Be Dragging Down Medtronic plc (NYSE:MDT) Stock - simplywall.st
Healthcare Digital Twins Market Size to Hit USD 6.80 Billion by 2032, growing at 25.7% CAGR, says Coherent Market Insights - GlobeNewswire Inc.
Medtronic plc (MDT): Among the Best High-Yield Dividend Stocks for 2025 and Beyond - Insider Monkey
Is Medtronic plc (MDT) the Best Medical Device Stock to Buy Now? - Insider Monkey
Medtronic (MDT) Rises Yet Lags Behind Market: Some Facts Worth Knowing - Yahoo Finance
Is Medtronic Stock a Buy Pre-Q4 Earnings? Key Metrics to Watch - The Globe and Mail
Medtronic to announce financial results for its fourth quarter and full fiscal year 2025 - The Globe and Mail
11 Best Medical Device Stocks to Buy Now - Insider Monkey
What Are Wall Street Analysts’ Target Price for Medtronic Stock? - Nasdaq
New survey: 1 in 3 women have not talked to their doctor about heart health, the #1 killer of women - Medtronic
Urology Surgical Instruments Market Top PlayersMedtronic, - openPR.com
What Are Wall Street Analysts’ Target Price For Medtronic Stock? - Barchart.com
Intubation Tubes Market Detailed in New Research Report By 2032 | - openPR.com
Medtronic (MDT) Surpasses Market Returns: Some Facts Worth Knowing - Yahoo Finance
A Look At The Fair Value Of Medtronic plc (NYSE:MDT) - Yahoo Finance
Medtronic (MDT) Rises Higher Than Market: Key Facts - Yahoo Finance
Medtronic wins FDA approval for defibrillation lead - MedTech Dive
Medtronic Education Program Opens Doors for Employees - Yahoo Finance
Medtronic study backs automated neuromod for overactive bladder - MassDevice
Medtronic and Abbott's game-changing partnership for CGM integration - Today's Medical Developments
4 PFA studies in the spotlight at Heart Rhythm 2025 - MedTech Dive
Earnings Preview: What To Expect From Medtronic’s Report - Nasdaq
Medtronic Gets FDA Nod for Smallest-Diameter, Lumenless Defibrillation Lead - Diagnostic and Interventional Cardiology
Medtronic has positive VenaSeal data - MassDevice
Functional Endoscopic Sinus Surgery Market Key Players - openPR.com
Medtronic submits Hugo soft tissue robot for FDA approval - MedTech Dive
Medtronic inks new distro agreement for Retia Medical Argos cardiac output monitor - MassDevice
The Zacks Analyst Blog Highlights Abbott Laboratories, Boston Scientific and Medtronic - Zacks Investment Research
Medtronic Trial for Robotic-Assisted Surgery System Meets Safety, Effectiveness Primary Endpoints - marketscreener.com
Medtronic’s defibrillation lead gains FDA approval for use in right ventricle - Yahoo Finance
Medtronic Files for FDA Submission for the Hugo Robotic System - Medical Device and Diagnostic industry
Medtronic Affera™ pulsed field ablation technologies continue to demonstrate promising evidence for atrial fibrillation patients - BioSpace
Smoke Evacuation System Market to Garner $196.4 Million by 2027 | - openPR.com
Medtronic receives US FDA approval for smallest-diameter, lumenless defibrillation lead, the OmniaSecure lead - Pharmabiz.com
Medtronic (MDT) Showcases Positive AFib Treatment Results at Key Medical Conference | MDT Stock News - GuruFocus
Medtronic (MDT) Reveals Promising AFib Treatment Outcomes with S - GuruFocus
Medtronic reports more positive outcomes with Affera PFA tech - MassDevice
Medtronic Affera pulsed field ablation technologies continue to demonstrate promising evidence for atrial fibrillation patients - Investing News Network
Medtronic PLC Says Sphere-360 Study Shows 88% Freedom From Arrhythmia Recurrence - marketscreener.com
Medtronic submits Hugo surgical robot to FDA, meets trial endpoints - MassDevice
Medtronic (MDT) Seeks FDA Approval for Hugo Robotic Surgery Syst - GuruFocus
Finanzdaten der Medtronic Plc-Aktie (MDT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):